Online version of the 2012-13 Department of Health and Ageing Annual Report

References

Page last updated: 29 October 2013

  1. Institute for Health Metrics and Evaluation, 2010 Global Burden of Disease Study.
  2. Myths and Realities: Number of deaths from diseases now vaccinated against in Australia, by decade 1926-2005.
  3. BreastScreen Australia monitoring report 2009-2010. Cancer Series no. 72 Cat. No. CAN 68. AIHW 2012.
  4. Breast cancer in Australia: an overview. Cancer series no. 71. Cat. no. CAN 67. Canberra: AIHW and Cancer Australia 2012.
  5. Cervical screening in Australia 2010-2011. Cancer series no. 76. Cat. no. CAN 72. Canberra: AIHW 2013.
  6. Fall in Human Papillomavirus Prevalence following a National Vaccination Program. Tabritzi S, Brotherton J, Kaldor J et al; Journal of Infectious Diseases 2012; 206(11):1645-51.
  7. Cancer in Australia: an overview, 2012. Cancer series no. 74. Cat. no. CAN 70. Canberra: AIHW - AIHW & AACR 2012.
  8. National Bowel Cancer Screening Program monitoring report Phase 2, July 2008 – June 2011. Cancer Series No. 65 CAN 61. Canberra: AIHW 2012.
  9. Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program. Cole SR, Tucker GR, Osborne JM, Byrne SE, Bampton PA , Fraser RJ and Young GP; Medical Journal of Australia 2013; 198 (6): 327-30.
  10. New flexible funds - program consolidation
  11. Tenders and grants
  12. Going mobile – my child's eHealth record mobile app
  13. Download the National Health Services Directory App
  14. Download the Quit for you Quit for two App
  15. Cancer Screening
  16. Australian Institute of Health and Welfare & Cancer Australia 2012, BreastScreen Australia monitoring report 2009-2010, Cancer series no. 72 Cat. no. CAN68 Canberra AIHW.
  17. Australian Institute of Health and Welfare & Cancer Australia 2012, Breast cancer in Australia : an overview. Cancer series no. 71 Cat. no. CAN67 Canberra AIHW.
  18. Australian Institute of Health and Welfare 2013. Cervical Screening in Australia 2010-2011. Cancer series 76. Cat. no. CAN 72. Canberra: AIHW.
  19. HPV School Vaccination Program
  20. Glycated Haemoglobin (HbA1c) Test: the HbA1c test shows an average blood glucose level over the previous 10-12 weeks.
  21. This pilot project is funded until 30 June 2014.
  22. Mid-term Review of the Implementation Plan: National Strategies 2010-2013 for Blood Borne Viruses and Sexually Transmissible Infections
  23. Alere Determine HIV 1/2 Ag/Ab Combo test.
  24. Notification period 1 July 2012 – 13 June 2013. Newly diagnosed cases for the period include notifications classified as either ‘newly acquired’ (infection acquired within 24 months prior to diagnosis) or ‘unspecified’ (infection acquired more than 24 months prior to diagnosis or not able to be specified).
  25. Newly diagnosed case for the period include notifications classified as either ‘newly acquired’ (infection acquired within 24 months prior to diagnosis) or ‘unspecified’ (infection acquired more than 24 months prior to diagnosis or not able to be specified).
  26. National Drug Strategy
  27. Australian Health Survey: Updated Results, 2011-12 (Table 13.3). Age standardised to the 2001 Australian population.
  28. The Australian Register of Therapeutic Goods
  29. Legislated timeframes relates to: 255 day timeframe for Design Examination Conformity Assessments for medical devices and for Category 1 prescription medicines applications; 45 days for Category 3 prescription medicines; and 60 days for a section 60 (of the Therapeutic Goods Act 1989) internal review.
  30. Category 1 refers to an application to register a new prescription medicine or change to a medicine not meeting the requirements for Category 2 or Category 3 applications. Category 3 refers to an application involving changes to the quality data of medicines already registered and not involving clinical, non-clinical or bioequivalence data. Category 2 refers to an application to register a prescription medicine where two independent evaluation reports from acceptable countries are available. TGA no longer reports on Category 2 evaluations as they are extremely rare.
  31. Delivering reforms - Implementation plan for TGA Reforms: A blueprint for TGA's future
  32. Perfluorinated chemicals are a large group of compounds that are widely used to make everyday products more resistant to stains and grease, or as a wetting agent. Certain perfluorinated chemicals are of concern around the world because they are not broken down in the environment and can persist for a long time, accumulating to levels that can be harmful to living systems.
  33. As detailed under the first deliverable, in July 2012, NICNAS started the process of assessing, over four years, around 3,000 existing chemicals using the IMAP framework. These first 3,000 chemicals are described as ‘Stage One Chemicals’.
  34. IMAP framework introduced in 2012-13.
  35. This includes 20 chemicals that were not included in the initial IMAP Stage One list of 3,000 chemicals. These are members of groups of chemicals already being assessed in Stage One and have been added to gain further efficiencies in the implementation of the IMAP framework.
  36. Fully immunised means vaccinated with the following antigens: hepatitis B, diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, measles, mumps and rubella (MMR).
  37. Tabritzi S. Brotherton J. Kaldor J et al. Fall in Human Papillomavirus Prevalence Following a National Vaccination Program, Journal of Infectious Diseases, 24 October 2012.
  38. Ali H et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. British Medical Journal 2013:346:f2032.
  39. HPV School Vaccination Program.
  40. Wave 1 data collection- the first collection of data in the ALSMH.
  41. The Kirby Institute, HIV, viral hepatitis and sexually transmissible infection in Australia Annual Surveillance Report 2012
  42. Hepatitis South Australia, Little Book of Hep C Facts
  43. Hepatitis Australia, Fast Facts on Hepatitis C
  44. Hepatitis Australia, Fast Facts on Hepatitis C
  45. Pharmaceutical Benefits Scheme (PBS)a
  46. Each cycle is identified by the year of the first reduction day after the end of its data collection period. This provides consistent naming for main and supplementary cycles and links each cycle to a time period. The 2013 Main Cycle was the second main EAPD cycle, where the end of the data collection period was 1 April 2013.
  47. Includes savings to both the PBS and the Repatriation Pharmaceutical Benefits Scheme.
  48. A genetic disease characterised by extremely fragile and blister prone skin.
  49. An opening in the abdomen for evacuation of products from the bowel or bladder.
  50. Figures as at 31 March 2013.
  51. A genetic disease characterised by extremely fragile and blister prone skin.
  52. The Medicare Teen Dental Plan operates on a calendar year basis. As such, estimates are for vouchers provided in the relevant calendar year.
  53. The Medicare Teen Dental Plan operates on a calendar year basis. As such, estimates are for vouchers provided in the relevant calendar year.
  54. Reciprocal Health Care Agreements provide access to public health services for Australian residents visiting certain countries, and for residents of those countries visiting Australia.
  55. The Australian Government has Reciprocal Health Care Agreements with New Zealand, the United Kingdom, the Republic of Ireland, Sweden, the Netherlands, Finland, Italy, Belgium, Malta, Slovenia and Norway.
  56. Out-of-pocket costs are those expenses which are not covered by Medicare, other government programs or private travel or health insurance.
  57. These figures are as per the Pathology Funding Agreement between the Australian Government and the pathology sector.
  58. AS 4700.2-2012: Implementation of Health Level Seven (HL7) Version 2.4 – Pathology and diagnostic imaging (diagnostics).
  59. This figure includes a facility that started treating patients in July 2013.
  60. My Aged Care and 1800 200 422.
  61. Commonwealth HACC program target population is: older people (people aged 65 years and over and Aboriginal and Torres Strait Islander people aged 50 years and over) and their carers, who live in the community and whose capacity for independent living is at risk, or who are at risk of premature or inappropriate admission to long term residential care. Victoria and Western Australian HACC population are not included in these figures.
  62. Commonwealth HACC program target population is: older people (people aged 65 years and over and Aboriginal and Torres Strait Islander people aged 50 years and over) and their carers, who live in the community and whose capacity for independent living is at risk, or who are at risk of premature or inappropriate admission to long term residential care. Victoria and Western Australian HACC population are not included in these figures.
  63. Estimated and incomplete data. The annual service delivery reports from service providers for 2012-13 were still being received at the time of publication.
  64. Aged Care Complains Scheme
  65. The complaints management process comprises four phases: intake, assessment, resolution and outcome. Early resolution refers to complaints resolved during the intake or assessment phase. Cases not resolved at early resolution progress to the resolution phase which utilises a range of techniques to resolve a complaint including service provider resolution, conciliation, investigation and mediation.
  66. National Health Services Directory
  67. Includes the Emerald GP Super Clinic which was delivered earlier than expected in June 2012.
  68. Regional, rural and remote Australia is classified using the Australian Standard Geographical Classification Remoteness Areas (ASGC-RA).
  69. Includes the projects that were delivered earlier than expected in June 2012.
  70. Phone 1800 899 538 or go to: Rural and Regional Health Australia
  71. In 2012-13, to be eligible to receive services under the Voucher Program, a person had to be an Australian Citizen or permanent resident 21 years or older and must have been either: a Pensioner Concession Card Holder; receiving Sickness Allowance from Centrelink; the holder of a Gold Repatriation Health Card issued for all conditions; the holder of a White Repatriation Health Card issued for conditions that include hearing loss; a dependant of a person in one of the above categories; a member of the Australian Defence Force; or undergoing an Australian Government funded disability management service and are referred by a disability employment services case manager.
  72. ABS and AIHW analysis of ABS mortality data 1998 to 2010 (unpublished) and includes jurisdictions for which data are available and of sufficient quality to publish (NSW, Qld, WA, SA and NT combined).
  73. A BS and AIHW analysis of ABS mortality data 1998 to 2010 (unpublished) and includes jurisdictions for which data are available and of sufficient quality to publish (NSW, Qld, WA, SA and NT combined).
  74. Source: NT Aboriginal Health Key Performance Indicators (AHKPIs) – KPI 1.7.
  75. Totals are cumulative over the life of the measure.
  76. ABS and AIHW analysis of ABS mortality data 1998 to 2010 (unpublished) and includes jurisdictions for which data are available and of sufficient quality to publish (NSW, Qld, WA, SA and NT combined).
  77. ABS and AIHW analysis of ABS mortality data 1998 to 2010 (unpublished) and includes jurisdictions for which data are available and of sufficient quality to publish (NSW, Qld, WA, SA and NT combined).
  78. Sourced from PHIAC June Quarterly Statistics
  79. Review of Health Technology Assessment in Australia.
  80. MyHospitals
  81. 1800 686 2 268
  82. Number of agreements excludes licenses, funding agreements for specific activities under other programs and reciprocal health care agreements.
  83. Serosurvey measures immunity in a population.
  84. Genotyping is a molecular technique that determines the genetic identity of viruses.
  85. Bacteria can be distinguished into serogroups determined by the type of polysaccharides present on the outer shell. Vaccines are available that protect against these bacteria by targeting their specific serogroup.
  86. Specialist Training Program places are allocated on a calendar/academic year basis.
  87. Evaluation of the mental health nurse incentive program
  88. Immunoglobulin products are derived from blood plasma and are used to provide protection against infection and modulate the immune system. These products can be administered to patients via subcutaneous route.
  89. Premium support is demand driven, with subsidies paid in response to applications from eligible doctors.
  90. Applications for a premium subsidy for 2012-13 can still be made until 30 June 2014.
  91. In 2012 the NEST reporting framework was introduced which provides performance reporting on a calendar year basis. Therefore an accurate overall figure cannot be provided for the 2012-13 financial year.
  92. In 2012 the NEAT reporting framework was introduced which provides performance reporting on a calendar year basis. Therefore an accurate overall figure cannot be provided for the 2012-13 financial year.
  93. This figure was indicative at the time of publication of the Portfolio Budget Statements as negotiations with states and territories had not commenced.
  94. Available at: Department of Health
  95. National Action Plan for Human Influenza Pandemic
  96. Injectable Opioid Analgesic – used for pain management and as an adjunct to general anaesthesia.
  97. Available at: Department of Finance
  98. Source: AIHW analysis of ABS Mortality Database (unpublished data). Data reported are for the jurisdictions with adequate levels of Indigenous identification (NSW, Qld, WA, SA, and NT combined).
  99. Source: AIHW analysis of ABS Mortality Database (unpublished data). Data reported are for the jurisdictions with adequate levels of Indigenous identification (NSW, Qld, WA, SA, and NT combined).
  100. Source: ABS (unpublished) National Health Survey, 2011-12.
  101. No new Indigenous data available (ABS Australian Aboriginal and Torres Strait Islander Health Survey 2012-13 will be released in November 2013).
  102. Source: ABS 43640DO003_20112012 Australian Health Survey: Updated Results, 2011–12, Australia.
  103. N o new Indigenous data available (ABS Australian Aboriginal and Torres Strait Islander Health Survey 2012-13 will be released in November 2013). Data is for Indigenous adults and is age-standardised using the 2001 Australian Estimated Resident population.
  104. Source: CRC 2013 /ABS Patient Experiences in Australia: Summary of Findings 2011-12.
  105. Source: CRC 2013/AIHW (unpublished) National Hospital Morbidity Database; ABS (unpublished) Estimated Resident Population, 30 June 2010; ABS (2009). Experimental Estimates and Projections, Aboriginal and Torres Strait Islander Australians, 1991 to 2021, 30 June 2009, Series B, Cat no. 3238.0.
  106. Source: CRC 2013/State and Territory (unpublished) community mental health care data; Private Mental Health Alliance (unpublished) Centralised Data Management Service data; Department of Health and Ageing (DoHA) (unpublished) MBS Statistics; Department of Veterans’ Affairs (DVA) (unpublished) data; Australian Bureau of Statistics (ABS) (unpublished) Estimate Resident Population, 30 June 2009.
  107. The costs reported cover only the amount paid to the organisation and not the cost of postage or production of the material sent out. Where a creative agency or direct marketing agency has been used to create the direct mail materials, the amount paid to the agency is reported here.
  108. Figures do not include 3 minor submissions considered at Special Meetings.
  109. Secretariat listings are not considered as a separate agenda item at a meeting of the Committee as they are very minor amendments to existing listings. However, all secretariat listings are still decided by the Committee on the merit of each application.
  110. Figures do not take into account extended meetings where two or more drugs are discussed within one meeting date.
  111. Available at: Pharmaceutical Benefits Scheme (PBS)
  112. Available at: Pharmaceutical Benefits Scheme (PBS)
  113. Available at: Pharmaceutical Benefits Scheme (PBS)
  114. Available at: Pharmaceutical Benefits Scheme (PBS)
  115. Available at: Pharmaceutical Benefits Scheme (PBS)
  116. Available at: Pharmaceutical Benefits Scheme (PBS)